Provided by Tiger Fintech (Singapore) Pte. Ltd.

IN8bio, Inc.

4.17
+0.567015.74%
Post-market: 3.79-0.3800-9.11%19:59 EDT
Volume:527.94K
Turnover:1.80M
Market Cap:12.62M
PE:-0.32
High:4.17
Open:3.58
Low:2.85
Close:3.60
Loading ...

IN8bio Raised to Buy From Hold by Jones Trading

Dow Jones
·
12 Feb

IN8bio upgraded to Buy from Hold at JonesResearch

TIPRANKS
·
11 Feb

JonesResearch upgrades IN8bio to Buy on ‘impressive’ AML data

TIPRANKS
·
11 Feb

IN8bio, Inc. : Jonestrading Raises to Buy Rating; Raises Target Price to $1.2

THOMSON REUTERS
·
11 Feb

IN8bio Says Data Show All Acute Myeloid Leukemia Patients in Early-Stage Study Remain Relapse-Free; Shares Up Pre-Bell

MT Newswires Live
·
11 Feb

IN8bio reports updated results from Phase 1 trial of INB-100

TIPRANKS
·
11 Feb

IN8bio, Inc. - 100% of Aml Patients Remain in Complete Remission

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Inb-100 Patients Show Prolonged Remissions Supported by Gamma-Delta T Cells

THOMSON REUTERS
·
11 Feb

IN8bio Reports Updated Positive Results From Phase 1 Trial of Inb-100 in Leukemia Patients

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Aml Patients Show One-Year Pfs and Os Exceeding Control Groups

THOMSON REUTERS
·
11 Feb

IN8bio, Inc. - Inb-100 Well-Tolerated With No Crs or Neurotoxicity

THOMSON REUTERS
·
11 Feb

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

GlobeNewswire
·
11 Feb

IN8bio to Present at Biotech Showcase 2025 in San Francisco

GlobeNewswire
·
06 Jan

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of Inb-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

GlobeNewswire
·
10 Dec 2024